Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -337.0%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $17M | $24M | $4M | $36M | $31M | $36M | $19M | $38M | $254M | — | — |
| Enterprise Value | $17M | $24M | $-987077 | $34M | $14M | $940333 | $2M | $34M | $238M | — | — |
| P/E Ratio → | -0.46 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.41 | 4.71 | 0.40 | 2.82 | 1.00 | 0.66 | 0.52 | 1.06 | 6.78 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | 100.0% | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | -13586.0% | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | -13586.0% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -337.0% | -337.0% | -121.7% | -82.4% | -55.8% | -78.0% | -87.6% | -106.1% | -70.4% | -57.1% | — |
| ROA | -185.2% | -185.2% | -82.1% | -64.1% | -46.6% | -67.3% | -74.7% | -95.5% | -67.2% | -51.5% | -637.3% |
| ROIC | -222.1% | -222.1% | -153.6% | -145.2% | -122.8% | -130.7% | -89.9% | -62.6% | — | -69.6% | — |
| ROCE | -197.0% | -197.0% | -138.2% | -109.4% | -64.7% | -74.4% | -84.3% | -60.9% | — | -57.1% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 0.08 | 0.03 | 0.02 | 0.01 | 0.01 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | -0.50 | -0.19 | -0.54 | -0.64 | -0.47 | -0.12 | -0.41 | -0.38 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -42.57 | -42.57 | -312.50 | -60970.87 | -545.96 | -487.99 | -119.77 | -218.43 | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | 1.07 | 1.80 | 2.43 | 2.28 | 5.28 | 4.82 | 1.25 | 12.94 | 4.26 | 0.12 |
| Quick Ratio | 1.06 | 1.06 | 1.79 | 2.43 | 2.28 | 5.28 | 4.82 | 1.15 | 12.94 | 4.26 | 0.12 |
| Cash Ratio | 1.02 | 1.02 | 1.08 | 0.77 | 2.17 | 4.07 | 3.14 | 0.87 | 12.12 | 3.74 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | 0.00 | — |
| Inventory Turnover | — | — | — | — | — | — | — | 2.88 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | 4143.64 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 8.1% | 6.3% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 8.1% | 6.3% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $3M | $1M | $609056 | $595882 | $537618 | $185291 | $108557 | $90848 | $101001 | $101001 |
Imminent liquidity shortfall
According to current market data, QNTM trades at a price-to-book ratio of 2.41, a valuation that appears to reflect a significant complexity discount rather than the intrinsic value of its clinical-stage assets, as reported in recent financial statements and market pricing metrics.
The lack of meaningful revenue or earnings renders traditional P/E or EV/EBITDA multiples irrelevant for assessing the company's fundamental value. Investors should monitor whether the market is pricing the firm based on its speculative drug pipeline or the liquidation value of its non-core residential loan portfolio.
Based on reported figures, the company's ROIC has exhibited extreme volatility, swinging from 81.2% in 2025Q4 to -27.5% in 2026Q1, which suggests that capital allocation is currently failing to generate sustainable returns as the firm navigates the high-cost phase of its clinical development cycle.
The erratic nature of these returns highlights the absence of a stable operational engine to compound invested capital. This trend warrants further investigation into whether management's strategic pivots are creating value or merely consuming shareholder equity to sustain administrative overhead.
As reported in recent financial filings, the current ratio has compressed to 0.63 in 2026Q1, indicating that the company's ability to cover short-term obligations is increasingly strained as cash reserves dwindle against the backdrop of ongoing Phase 2 clinical trial expenditures.
A current ratio below unity suggests that the firm may face immediate pressure to secure additional financing to avoid a liquidity crisis. Investors should monitor the company's cash runway closely, as the current burn rate appears to leave little room for operational delays or unforeseen regulatory hurdles.
Based on the provided financial data, the company's debt-to-equity ratio has fluctuated significantly, reaching 0.37 in 2025Q4, which suggests that even modest debt levels may become burdensome given the total absence of recurring operational revenue to support interest payments.
While the debt load appears manageable in absolute terms, the lack of cash flow generation makes any leverage a potential risk factor for shareholders. The company's reliance on external capital markets for survival implies that debt service capacity is entirely dependent on the success of future equity raises.
As evidenced by the company's financial history, the use of net margin as a performance indicator is fundamentally misapplied to this business model, as it obscures the massive R&D-driven cash burn that defines the firm's current operational reality.
Investors should instead focus on the cash burn rate and the clinical milestone timeline, as net income is frequently distorted by non-operating items and accounting adjustments. Relying on standard profitability ratios in a pre-revenue biotech context may lead to a dangerous underestimation of the firm's actual financial risk.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying QNTM stock.
Quantum BioPharma Ltd.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Quantum BioPharma Ltd.'s return on equity (ROE) is -337.0%. The historical average is -110.7%.
Based on historical data, Quantum BioPharma Ltd. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.